Key Points
- Incyte EVP Mohamed Khairie Issa sold 10,856 shares at an average of $109.07 for a total of $1,184,063.92, reducing his stake by 14.10% to 66,132 shares per an SEC Form 4 filing — a move that may be viewed as insider profit‑taking.
- Major clinical catalysts — including positive Phase‑3 frontMIND and top‑line Phase‑III tafasitamab results in DLBCL — alongside bullish analyst commentary (Morgan Stanley, Barclays) have strengthened the stock's near‑term outlook.
- Incyte posted a strong quarter with $2.26 EPS (beat) and revenue of $1.37B (up 20%), and currently has a market cap of about $20.8B, a P/E of ~17.7 and a 52‑week range of $53.56–$112.29.
Incyte Corporation (NASDAQ:INCY - Get Free Report) EVP Mohamed Khairie Issa sold 10,856 shares of the business's stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $109.07, for a total transaction of $1,184,063.92. Following the transaction, the executive vice president owned 66,132 shares of the company's stock, valued at $7,213,017.24. This represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Incyte Price Performance
Shares of INCY opened at $105.92 on Friday. The business's 50-day moving average is $101.84 and its two-hundred day moving average is $87.82. The company has a market capitalization of $20.79 billion, a P/E ratio of 17.74, a P/E/G ratio of 0.67 and a beta of 0.82. Incyte Corporation has a fifty-two week low of $53.56 and a fifty-two week high of $112.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.13 and a current ratio of 3.20.
Incyte (NASDAQ:INCY - Get Free Report) last issued its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $2.26 EPS for the quarter, topping analysts' consensus estimates of $1.65 by $0.61. Incyte had a return on equity of 26.56% and a net margin of 24.69%.The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.26 billion. During the same quarter in the prior year, the business earned $1.07 earnings per share. The company's revenue was up 20.0% compared to the same quarter last year. Research analysts predict that Incyte Corporation will post 4.86 earnings per share for the current year.
More Incyte News
Here are the key news stories impacting Incyte this week:
Institutional Trading of Incyte
Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in shares of Incyte by 0.7% in the second quarter. Vanguard Group Inc. now owns 20,135,393 shares of the biopharmaceutical company's stock valued at $1,371,220,000 after buying an additional 137,570 shares in the last quarter. AQR Capital Management LLC boosted its holdings in Incyte by 21.8% during the 2nd quarter. AQR Capital Management LLC now owns 8,201,455 shares of the biopharmaceutical company's stock valued at $558,519,000 after acquiring an additional 1,465,286 shares during the period. Geode Capital Management LLC grew its position in Incyte by 3.3% in the 2nd quarter. Geode Capital Management LLC now owns 4,347,731 shares of the biopharmaceutical company's stock valued at $294,899,000 after acquiring an additional 139,740 shares in the last quarter. LSV Asset Management increased its stake in Incyte by 3.2% during the third quarter. LSV Asset Management now owns 3,986,097 shares of the biopharmaceutical company's stock worth $338,061,000 after purchasing an additional 124,266 shares during the period. Finally, Invesco Ltd. lifted its position in shares of Incyte by 7.3% during the second quarter. Invesco Ltd. now owns 3,401,018 shares of the biopharmaceutical company's stock worth $231,609,000 after purchasing an additional 232,268 shares in the last quarter. Institutional investors and hedge funds own 96.97% of the company's stock.
Wall Street Analyst Weigh In
Several research firms recently weighed in on INCY. Truist Financial set a $103.00 price target on shares of Incyte in a research report on Wednesday, December 24th. Morgan Stanley raised their target price on Incyte from $92.00 to $94.00 and gave the stock an "equal weight" rating in a research note on Tuesday. The Goldman Sachs Group reissued a "neutral" rating and issued a $90.00 price objective on shares of Incyte in a report on Thursday. Stifel Nicolaus set a $119.00 price objective on shares of Incyte in a research report on Monday. Finally, Zacks Research lowered shares of Incyte from a "strong-buy" rating to a "hold" rating in a report on Monday, November 10th. Eight investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Incyte has an average rating of "Hold" and an average price target of $99.53.
Check Out Our Latest Stock Analysis on INCY
Incyte Company Profile
(
Get Free Report)
Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company's research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.
The company's flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
